Cell and gene therapies, as well as viral vaccines, need higher production yields—and that's where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses. Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.